An Efficacy and Safety Study of Infliximab Dose Escalation in Pediatric Participants With Inflammatory Bowel Disease (ADAPT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02566889
Recruitment Status : Recruiting
First Posted : October 2, 2015
Last Update Posted : November 29, 2018
Information provided by (Responsible Party):
Janssen Scientific Affairs, LLC

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : August 6, 2029
  Estimated Study Completion Date : August 6, 2030